Acrolein induces Alzheimer's disease-like pathologies in vitro and in vivo

Toxicology Letters

Volumn 217, Issue 3, 2013, Pages 184-191

  Huang, Ying Juan ^a   Jin, Ming Hua ^a   Pi, Rong Biao ^a   Zhang, Jun Jie ^a   Ouyang, Ying ^a   Chao, Xiao Juan ^a   Chen, Mei Hui ^a   Liu, Pei Qing ^a   Yu, Jian Chen ^a   Ramassamy, Charles ^b   Dou, Juan ^a   Chen, Xiao Hong ^a   Jiang, Yi Ming ^a   Qin, Jian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Acrolein; Alzheimer's disease; Neurotoxicity; Oxidative stress

Indexed keywords

ACROLEIN; ADAM10 ENDOPEPTIDASE; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN LEVEL; BRAIN TISSUE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPATIAL LEARNING; UPREGULATION;

ACROLEIN; ADAM PROTEINS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; CELL LINE; CELL SURVIVAL; COGNITION; DISINTEGRINS; IMMUNOHISTOCHEMISTRY; MICE; NEURONS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84873268851     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.12.023     Document Type: Article

References (51)

1. Ansari M.A., Keller J.N., Scheff S.W. Protective effect of Pycnogenol in human neuroblastoma SH-SY5Y cells following Acrolein-induced cytotoxicity. Free Radical Biology and Medicine 2008, 45:1510-1519.
2. Belkacemi A., Ramassamy C. Time sequence of oxidative stress in the brain from transgenic mouse models of Alzheimer's disease related to the amyloid-beta cascade. Free Radical Biology and Medicine 2012, 52:593-600.
3. Black A.T., Gray J.P., Shakarjian M.P., Laskin D.L., Heck D.E., Laskin J.D. Increased oxidative stress and antioxidant expression in mouse keratinocytes following exposure to paraquat. Toxicology and Applied Pharmacology 2008, 231:384-392.
4. Bradley M.A., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and Acrolein in the brain in preclinical Alzheimer disease. Free Radical Biology and Medicine 2010, 48:1570-1576.
5. Choi B.R., Lee S.R., Han J.S., Woo S.K., Kim K.M., Choi D.H., Kwon K.J., Han S.H., Shin C.Y., Lee J., Chung C.S., Kim H.Y. synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amlyloid toxicity in a rat model. Stroke 2011, 42:2595-2604.
6. Conklin D.J., Barski O.A., Lesgards J.F., Juvan P., Rezen T., Rozman D., Prough R.A., Vladykovskaya E., Liu S., Srivastava S., Bhatnagar A. Acrolein consumption induces systemic dyslipidemia and lipoprotein modification. Toxicology and Applied Pharmacology 2010, 243:1-12.
7. Deane R., Bell R.D., Sagare A., Zlokovic B.V. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS & Neurological Disorders Drug Targets 2009, 8:16-30.
8. Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2006, 65:866-872.
9. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses β-amyloid production by activating the α-secretase gene ADAM10. Cell 2010, 142:320-332.
10. Epis R., Marcello E., Gardoni F., Vastagh C., Malinverno M., Balducci C., Colombo A., Borroni B., Vara H., Dell'Agli M., Cattabeni F., Giustetto M., Borsello T., Forloni G., Padovani A., Di Luca M. Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. Brain 2010, 133:3323-3335.
11. Fukui M., Choi H.J., Zhu B.T. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radical Biology and Medicine 2010, 49:800-813.
12. Galimberti D., Scarpini E. Progress in Alzheimer's disease. Journal of Neurology 2012, 259:201-211.
13. Gomez-Ramos A., Diaz-Nido J., Smith M.A., Perry G., Avila J. Effect of the lipid peroxidation product Acrolein on tau phosphorylation in neural cells. Journal of Neuroscience Research 2003, 71:863-870.
14. Hamann K., Nehrt G., Ouyang H., Duerstock B., Shi R. Hydralazine inhibits compression and Acrolein-mediated injuries in ex vivo spinal cord. Journal of Neurochemistry 2008, 104:708-718.
15. Hamann K., Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. Journal of Neurochemistry 2009, 111:1348-1356.
16. Hashioka S., Klegeris A., McGeer P.L. Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology 2012, 63:685-691.
17. Hayashi H., Tohda M., Watanabe H., Murakami Y., Matsumoto K. The effects of Choto-san on the mRNA expression of Alzheimer's disease related factors in the permanent ischemic rat brain. Biological and Pharmaceutical Bulletin 2005, 28:744-746.
18. Ismahil M.A., Hamid T., Haberzettl P., Gu Y., Chandrasekar B., Srivastava S., Bhatnagar A., Prabhu S.D. Chronic oral exposure to the aldehyde pollutant Acrolein induces dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology 2011, 301:H2050-H2060.
19. Kawaguchi-Niida M., Shibata N., Morikawa S., Uchida K., Yamamoto T., Sawada T., Kobayashi M. Crotonaldehyde accumulates in glial cells of Alzheimer's disease brain. Acta Neuropathologica 2006, 111:422-429.
20. Kim D., Tsai L.H. Bridging physiology and pathology in AD. Cell 2009, 137:997-1000.
21. Kitaguchi H., Tomimoto H., Ihara M., Shibata M., Uemura K., Kalaria R.N., Kihara T., Asada-Utsugi M., Kinoshita A., Takahashi R. Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Research 2009, 1294:202-210.
22. Kitazawa M., Cheng D., Laferla F.M. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. Journal of Neurochemistry 2009, 108:1550-1560.
23. Kuhla B., Haase C., Flach K., Luth H.J., Arendt T., Munch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. Journal of Biological Chemistry 2007, 282:6984-6991.
24. Leung G., Sun W., Zheng L., Brookes S., Tully M., Shi R. Anti-Acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouse. Neuroscience 2011, 173:150-155.
25. Liu J., Li L., Suo W.Z. HT22 hippocampal neuronal cell line possesses functional cholinergic properties. Life Sciences 2009, 84:267-271.
26. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiology of Aging 2001, 22:187-194.
27. Milane L., Duan Z., Amiji M. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS ONE 2011, 6:e24075.
28. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
29. Mracsko E., Hugyecz M., Institoris A., Farkas E., Bari F. Changes in pro-oxidant and antioxidant enzyme levels during cerebral hypoperfusion in rats. Brain Research 2010, 1321:13-19.
30. Murray I.V., Proza J.F., Sohrabji F., Lawler J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Experimental Biology and Medicine (Maywood) 2011, 236:772-782.
31. Nam D.T., Arseneault M., Murthy V., Ramassamy C. Potential role of Acrolein in neurodegeneration and in Alzheimer's disease. Current Molecular Pharmacology 2010, 3:66-78.
32. Nam D.T., Arseneault M., Ramassamy C. Regulation of redox-sensitive signaling pathways in rat primary astrocytes following Acrolein exposure. Journal of Alzheimer's Disease 2011, 25:263-277.
33. Nam D.T., Arseneault M., Zarkovic N., Waeg G., Ramassamy C. Molecular regulations induced by Acrolein in neuroblastoma SK-N-SH cells: relevance to Alzheimer's disease. Journal of Alzheimer's Disease 2010, 21:1197-1216.
34. Pi R., Mao X., Chao X., Cheng Z., Liu M., Duan X., Ye M., Chen X., Mei Z., Liu P., Li W., Han Y. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo. PLoS ONE 2012, 7:e31921.
35. Rat D., Schmitt U., Tippmann F., Dewachter I., Theunis C., Wieczerzak E., Postina R., van Leuven F., Fahrenholz F., Kojro E. Neuropeptide pituitary adenylatecyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB Journal 2011, 25:3208-3218.
36. Sakata T., Smith R.A., Garland E.M., Cohen S.M. Rat urinary bladder epithelial lesions induced by Acrolein. Journal of Environmental Pathology, Toxicology and Oncology 1989, 9:159-169.
37. Satoh K., Yamada S., Koike Y., Igarashi Y., Toyokuni S., Kumano T., Takahata T., Hayakari M., Tsuchida S., Uchida K. A 1-hour enzyme-linked immunosorbent assay for quantitation of Acrolein- and hydroxynonenal-modified proteins by epitope-bound casein matrix method. Analytical Biochemistry 1999, 270:323-328.
38. Seidler N.W., Squire T.J. Abeta-polyacrolein aggregates: novel mechanism of plastic formation in senile plaques. Biochemical and Biophysical Research Communications 2005, 335:501-504.
39. Sharma N.K., Sethy N.K., Meena R.N., Ilavazhagan G., Das M., Bhargava K. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain. Peptides 2011, 32:1217-1224.
40. Shi R., Rickett T., Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Molecular Nutrition & Food Research 2011, 55:1320-1331.
41. Singh M., Nam D.T., Arseneault M., Ramassamy C. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on Acrolein. Journal of Alzheimer's Disease 2010, 21:741-756.
42. Srivastava S., Sithu S.D., Vladykovskaya E., Haberzettl P., Hoetker D.J., Siddiqui M.A., Conklin D.J., D'Souza S.E., Bhatnagar A. Oral exposure to Acrolein exacerbates atherosclerosis in apoE-null mice. Atherosclerosis 2011, 215:301-308.
43. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 19:341-353.
44. Sultana R., Perluigi M., Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radical Biology & Medicine 2012, S0891-5849(12):1161-1166.
45. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. Journal of Neurochemistry 2005, 92:628-636.
46. Wang G.W., Guo Y., Vondriska T.M., Zhang J., Zhang S., Tsai L.L., Zong N.C., Bolli R., Bhatnagar A., Prabhu S.D. Acrolein consumption exacerbates myocardial ischemic injury and blocks nitric oxide-induced PKCepsilon signaling and cardioprotection. Journal of Molecular and Cellular Cardiology 2008, 44:1016-1022.
47. Waragai M., Yoshida M., Mizoi M., Saiki R., Kashiwagi K., Takagi K., Arai H., Tashiro J., Hashimoto M., Iwai N., Uemura K., Igarashi K. Increased protein-conjugated Acrolein and Amyloid-beta40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease 2012, 32:33-41.
48. Weinhold B. Acrolein and neuro disorders. Environmental Health Perspectives 2011, 119:A68.
49. Williams T.I., Lynn B.C., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and Acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiology of Aging 2006, 27:1094-1099.
50. Xu J., Wang Y., Li N., Xu L., Yang H., Yang Z. l-3-n-Butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology 2012, 62:2424-2429.
51. Zhang X.M., Cai Y., Xiong K., Cai H., Luo X.G., Feng J.C., Clough R.W., Struble R.G., Patrylo P.R., Yan X.X. β-Secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. European Journal of Neuroscience 2009, 30:2271-2283.